Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1979 Sep;16(2):101-5.
doi: 10.1007/BF00563115.

Pharmacokinetics of dihydroquinidine in congestive heart failure patients after intravenous quinidine administration

Pharmacokinetics of dihydroquinidine in congestive heart failure patients after intravenous quinidine administration

C T Ueda et al. Eur J Clin Pharmacol. 1979 Sep.

Abstract

The pharmacokinetics of dihydroquinidine were studied in 8 patients with congestive heart failure following a 22 min intravenous infusion of a quinidine preparation that contained 5.9% dihydroquinidine as an impurity. Using a thin layer chromatography-fluorometric assay procedure for dihydroquinidine, the post-infusion plasma dihydroquinidine concentrations declined biexponentially. The half-life of the fast and slow dispositional processes was 4.42 +/- 1.81 min and 6.52 +/- 2.40 h, respectively. The central compartment volume for dihydroquinidine in these patients was 0.44 +/- 0.11 l/kg with an overall apparent volume of distribution of 1.14 +/- 0.38 l/kg. The computed values of total body plasma clearance of dihydroquinidine ranged from 1.29 to 2.69 ml/min/kg with a mean value of 1.94 +/- 0.60 ml/min/kg. In these patients, approximately 16% of the administered dihydroquinidine dose was excreted intact into the urine in 48 h. The estimated value of renal clearance was 0.314 +/- 0.129 ml/min/kg. When compared to control cardiac patients, the data showed that the apparent volume of distribution for dihydroquinidine is smaller in patients with congestive heart failure and as a result of this diminished volume, the clearance rate of dihydroquinidine was slower. The net effect of these differences was the production of higher plasma concentrations of dihydroquinidine in the heart failure group.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Clin Pharmacokinet. 1976;1(5):339-50 - PubMed
    1. Drug Metab Rev. 1975;4(2):139-75 - PubMed
    1. Clin Pharmacokinet. 1976;1(2):99-120 - PubMed
    1. Res Commun Chem Pathol Pharmacol. 1976 Jun;14(2):215-25 - PubMed
    1. J Pharm Sci. 1978 Oct;67(10):1355-7 - PubMed

LinkOut - more resources